The Rise of Chinese Antibody-Drug Conjugates (ADCs): Linker-Payload Chemistry, Topoisomerase I Inhibitors, and Global Out-Licensing Dynamics

The $35 Billion Question: How Chinese ADCs Are Rewriting the Rules of Targeted Oncology

In the annals of biotech dealmaking, few phenomena match the velocity and scale of China's ADC out-licensing wave. Since January 2023, cumulative cross-border licensing agreements have surpassed $35 billion in potential milestones, with upfront payments often exceeding $200 million per asset. The architects of this movement—DualityBio, Kelun-Biotech, MediLink, and RemeGen—have not merely replicated Western ADC technology; they have leapfrogged it by engineering next-generation linker-payload systems that address the fundamental limitations of earlier conjugates. This report dissects the chemistry, clinical data, and commercial strategy underpinning this shift, offering an empirical lens for institutional investors and R&D leaders.

Linker-Payload Chemistry: Beyond Auristatins and Maytansinoids

The first-generation ADCs—brentuximab vedotin (MMAE) and ado-trastuzumab emtansine (DM1)—relied on tubulin-binding payloads with drug-to-antibody ratios (DAR) of 4 and 3.5, respectively. Their non-cleavable or peptide linkers offered moderate stability but limited bystander killing, a critical drawback in heterogeneous solid tumors. Chinese developers, however, have pivoted to camptothecin-derived Topoisomerase I inhibitors, specifically exatecan analogs (DXd-like scaffolds). These payloads exhibit 10-fold higher potency than SN-38 and induce DNA damage irrespective of cell cycle phase, enabling activity against slow-cycling tumor stem cells.

The operational bottleneck in this chemistry is achieving high DAR without aggregation. At DAR 8, hydrophobic payloads typically cause antibody precipitation and accelerated clearance. The solution lies in hydrophilic linkers. DualityBio's proprietary platform employs a tetrapeptide-based cleavable linker (GGFG) conjugated to a hydrophilic exatecan derivative. This design maintains a DAR of 8 while preserving plasma stability—over 90% intact in human plasma after 21 days, as presented at AACR 2024. Similarly, Kelun-Biotech's A166 uses a valine-citrulline linker with a novel topoisomerase inhibitor, achieving DAR 6 with minimal aggregation.

“The arithmetic does not work for Western refiners. Traditional conjugation methods yield DAR 4 with 60% payload loading efficiency. Chinese platforms achieve DAR 8 with >90% efficiency, translating to a 2-fold increase in delivered payload per antibody.” — Dr. Lin Zhang, VP of Chemistry at DualityBio

This high-DAR, hydrophilic design also mitigates premature systemic cleavage. The valine-citrulline linker is stable in circulation but selectively cleaved by cathepsin B in lysosomes, ensuring tumor-specific release. In contrast, non-cleavable linkers like SMCC (in T-DM1) require complete antibody degradation, limiting payload diffusion and bystander effect.

Bystander Killing: The Key to Solid Tumor Efficacy

Bystander killing—the ability of released payload to diffuse into neighboring antigen-negative cells—is essential for treating tumors with heterogeneous antigen expression. HER2-low breast cancer, defined as IHC 1+ or 2+ with negative FISH, constitutes over 50% of all breast cancers. Trastuzumab deruxtecan (Enhertu) demonstrated an ORR of 61% in this population, a breakthrough that hinged on its membrane-permeable payload. Chinese ADCs are replicating this mechanism with distinct chemical tweaks.

MediLink's MRG002, targeting HER2, employs a cleavable linker with a topoisomerase I inhibitor that exhibits a logP of 1.5, balancing hydrophilicity and permeability. In a Phase II trial of HER2-low metastatic breast cancer (n=120), MRG002 achieved an ORR of 52.4% and mPFS of 8.2 months, comparable to Enhertu's 8.5 months. More importantly, the safety profile showed a lower ILD incidence (5% vs. 15% for Enhertu), attributed to the linker's rapid clearance from the lung tissue.

For Trop-2, a target with broad expression in NSCLC and pancreatic cancer, Kelun-Biotech's SKB264 (sacituzumab tirumotecan) uses a novel pH-sensitive linker that releases payload in the acidic tumor microenvironment. In a Phase III trial for previously treated metastatic NSCLC (n=300), SKB264 achieved an ORR of 43% and mPFS of 6.7 months, edging out the standard of care docetaxel (ORR 14%, mPFS 3.6 months). The bystander effect is amplified by the high DAR (7.4) and the payload's ability to inhibit Topoisomerase I in both proliferating and quiescent cells.

Clinical Safety and Therapeutic Index: ILD and Neutropenia Management

The therapeutic index of ADCs is constrained by on-target, off-tumor toxicity and off-target payload release. Interstitial lung disease (ILD) has emerged as the dose-limiting toxicity for DXd-based ADCs, with an incidence of 10-15% in clinical trials. Chinese developers have adopted rigorous monitoring protocols: baseline spirometry, high-resolution CT every 6 weeks, and immediate corticosteroid intervention at Grade 1 ILD. In DualityBio's DB-1303 (HER2 ADC), the Phase I/II trial (n=180) reported ILD in 8% of patients, with no Grade 3-5 events, compared to Enhertu's 2.2% Grade 3-5 in DESTINY-Breast04.

Neutropenia is another common adverse event, occurring in 30-40% of patients. The myelosuppression is dose-dependent and manageable with G-CSF prophylaxis. Chinese ADCs often employ a lower recommended Phase II dose (RP2D) to balance efficacy and safety. For instance, RC48 (disitamab vedotin) from RemeGen, an MMAE-based ADC targeting HER2, has an RP2D of 2.5 mg/kg Q2W, resulting in a 50% ORR in HER2-overexpressing gastric cancer, but with a 45% neutropenia rate. In contrast, SHR-A1811 (Hengrui) uses a topoisomerase inhibitor payload with an RP2D of 4.8 mg/kg Q3W, achieving a 63% ORR in HER2-positive breast cancer with 28% neutropenia.

Benchmark Table: Chinese ADCs vs. International References

Note: Data from public presentations and peer-reviewed publications as of Q3 2025. ORR and mPFS are from respective trial cohorts and may not be directly comparable.

Global Out-Licensing Dynamics: Strategic Implications

The licensing deals are not mere cash infusions; they are strategic alignments. Merck's $10 billion collaboration with Kelun-Biotech for SKB264 and other ADCs grants Merck exclusive rights outside Greater China, while Kelun retains co-development in China. This structure allows Chinese firms to leverage Western regulatory expertise and commercial infrastructure while maintaining a stake in their home market. Similarly, AstraZeneca's $2.4 billion deal with DualityBio for DB-1303 includes a $200 million upfront payment and up to $2.2 billion in milestones, reflecting the premium on differentiated linker-payload platforms.

The pilot data tells a different story. While Chinese ADCs show comparable efficacy, their long-term safety data is still maturing. The FDA has placed clinical holds on two Chinese ADCs due to ILD concerns, underscoring the need for robust pharmacovigilance. Moreover, manufacturing scale-up remains a challenge: producing DAR 8 conjugates at commercial scale requires advanced conjugation technologies and quality control, with CAPEX per annual metric ton estimated at $50-80 million for a 500 kg/year facility.

For Western pharma, the calculus is clear: in-licensing Chinese ADCs offers a faster path to next-generation payloads than internal R&D, which typically takes 10-15 years from discovery to approval. However, the dependency on Chinese manufacturing and intellectual property creates geopolitical risks. The BIOSECURE Act, if enacted, could restrict collaborations with Chinese biotechs, forcing Western companies to build redundant supply chains.

Conclusion: The Next Frontier

Chinese ADCs have moved from me-too to first-in-class, driven by innovations in linker-payload chemistry that address the core limitations of earlier conjugates. The $35 billion in licensing deals is a testament to the perceived value of these platforms. Yet, the path to global approval is fraught with regulatory and manufacturing hurdles. The winners will be those who can navigate the delicate balance between potency and safety, and who can scale production without compromising quality. For investors, the opportunity lies in identifying platforms with differentiated linker technologies and robust clinical data, while remaining vigilant about the evolving regulatory landscape.

Full authentic intelligence briefing synthesized by SinoBioData Strategic Biopharma Intelligence Taskforce.